Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients

NCT05077969 is registered in ClinicalTrials.gov with Leidos Life Sciences as lead sponsor.

NCT NCT05077969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients
Lead sponsor
Leidos Life Sciences
Phase
Phase 2
Overall status
Terminated
Start date
December 29, 2021
Completion date
July 8, 2022
Enrollment
4 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

2019 novel coronavirus disease, 2019 novel coronavirus infection, 2019-ncov disease, 2019-ncov infection, coronavirus disease 2019, covid-19, covid-19 pandemic, covid-19 virus disease, covid-19 virus infection, covid19, sars-cov-2 acute respiratory disease, sars-cov2 infection